Crossmark

CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease

Crossref DOI link: https://doi.org/10.1016/j.omtn.2018.03.007

Published Print: 2018-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

György, Bence

Lööv, Camilla

Zaborowski, Mikołaj P.

Takeda, Shuko

Kleinstiver, Benjamin P.

Commins, Caitlin

Kastanenka, Ksenia

Mu, Dakai

Volak, Adrienn

Giedraitis, Vilmantas

Lannfelt, Lars

Maguire, Casey A.

Joung, J. Keith

Hyman, Bradley T.

Breakefield, Xandra O.

Ingelsson, Martin
Funding

Funding for this research was provided by:

National Institutes of Health

National Institute of General Medical Sciences (R35 118158)

National Center for Research Resources (1S10RR028832-01)

Kosciuszko Foundation

Natural Sciences and Engineering Research Council of Canada

Marianne and Marcus Wallenberg Foundation (U19 CA179563)
License Information

Text and Data Mining valid from 2018-06-01

Text and Data Mining valid from 2018-06-01

Version of Record valid from 2018-03-13
More Information

This article is maintained by: Elsevier

Article Title: CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease

Journal Title: Molecular Therapy Nucleic Acids

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.omtn.2018.03.007

Content Type: article

Copyright: © 2018 The Author(s).